ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

Solange Peters

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

Share this video